This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ednie, L. M.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ednie, L. M.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 4027-4032, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4027-4032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents

Lois M. Ednie, Glenn Pankuch, and Peter C. Appelbaum*

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania

Received 4 June 2004/ Returned for modification 16 June 2004/ Accepted 24 June 2004

The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 µg/ml for 300 pneumococci, irrespective of their ß-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs ≤2.0 µg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the ß-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.

* Corresponding author. Mailing address: Department of Pathology, Penn State Hershey Medical Center, 500 University Dr., H160, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu.

Antimicrobial Agents and Chemotherapy, October 2004, p. 4027-4032, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4027-4032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Caughlan, R. E., Sriram, S., Daigle, D. M., Woods, A. L., Buco, J., Peterson, R. L., Dzink-Fox, J., Walker, S., Dean, C. R. (2009). Fmt Bypass in Pseudomonas aeruginosa Causes Induction of MexXY Efflux Pump Expression. Antimicrob. Agents Chemother. 53: 5015-5021 [Abstract] [Full Text]  
  • Osborne, C. S., Neckermann, G., Fischer, E., Pecanka, R., Yu, D., Manni, K., Goldovitz, J., Amaral, K., Dzink-Fox, J., Ryder, N. S. (2009). In Vivo Characterization of the Peptide Deformylase Inhibitor LBM415 in Murine Infection Models. Antimicrob. Agents Chemother. 53: 3777-3781 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Credito, K. L., Pankuch, G. A., DeWasse, B., McGhee, P., Appelbaum, P. C. (2007). Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents. Antimicrob. Agents Chemother. 51: 770-773 [Abstract] [Full Text]  
  • Bogdanovich, T., Smith, K. A., Clark, C., Pankuch, G. A., Lin, G., McGhee, P., Dewasse, B., Appelbaum, P. C. (2006). Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species.. Antimicrob. Agents Chemother. 50: 2323-2329 [Abstract] [Full Text]  
  • Watters, A. A., Jones, R. N., Leeds, J. A., Denys, G., Sader, H. S., Fritsche, T. R. (2006). Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother 57: 914-923 [Abstract] [Full Text]  
  • Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D. (2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 4128-4136 [Abstract] [Full Text]  
  • Fritsche, T. R., Sader, H. S., Cleeland, R., Jones, R. N. (2005). Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. Antimicrob. Agents Chemother. 49: 1468-1476 [Abstract] [Full Text]  
  • Bell, J. M., Turnidge, J. D., Inoue, M., Kohno, S., Hirakata, Y., Ono, Y., Jones, R. N. (2005). Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother 55: 276-278 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»